Mainz Biomed (MYNZ) Competitors $1.43 +0.00 (+0.07%) As of 01:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MYNZ vs. CARM, BIVI, QTTB, MTEX, AYTU, ERNA, CING, LGVN, BLRX, and LEXXShould you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include Carisma Therapeutics (CARM), BioVie (BIVI), Q32 Bio (QTTB), Mannatech (MTEX), Aytu BioPharma (AYTU), Ernexa Therapeutics (ERNA), Cingulate (CING), Longeveron (LGVN), BioLineRx (BLRX), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical products" industry. Mainz Biomed vs. Its Competitors Carisma Therapeutics BioVie Q32 Bio Mannatech Aytu BioPharma Ernexa Therapeutics Cingulate Longeveron BioLineRx Lexaria Bioscience Carisma Therapeutics (NASDAQ:CARM) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation. Do institutionals and insiders believe in CARM or MYNZ? 44.3% of Carisma Therapeutics shares are held by institutional investors. 12.6% of Carisma Therapeutics shares are held by insiders. Comparatively, 18.2% of Mainz Biomed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor CARM or MYNZ? In the previous week, Carisma Therapeutics had 3 more articles in the media than Mainz Biomed. MarketBeat recorded 4 mentions for Carisma Therapeutics and 1 mentions for Mainz Biomed. Carisma Therapeutics' average media sentiment score of 0.00 equaled Mainz Biomed'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carisma Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings and valuation, CARM or MYNZ? Mainz Biomed has lower revenue, but higher earnings than Carisma Therapeutics. Carisma Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.86-$60.48M-$1.56-0.26Mainz Biomed$890K5.53-$21.65M-$65.60-0.02 Which has more volatility & risk, CARM or MYNZ? Carisma Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Is CARM or MYNZ more profitable? Mainz Biomed has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-254.28% N/A -137.38% Mainz Biomed N/A N/A N/A Do analysts rate CARM or MYNZ? Carisma Therapeutics currently has a consensus price target of $1.93, indicating a potential upside of 375.31%. Mainz Biomed has a consensus price target of $14.00, indicating a potential upside of 878.34%. Given Mainz Biomed's stronger consensus rating and higher possible upside, analysts clearly believe Mainz Biomed is more favorable than Carisma Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.43Mainz Biomed 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryMainz Biomed beats Carisma Therapeutics on 8 of the 14 factors compared between the two stocks. Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYNZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYNZ vs. The Competition Export to ExcelMetricMainz BiomedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.92M$2.90B$5.50B$9.01BDividend YieldN/A2.64%5.39%4.11%P/E Ratio-0.0221.5027.4220.07Price / Sales5.53282.64398.50109.13Price / CashN/A41.4736.1356.90Price / Book0.557.518.015.70Net Income-$21.65M-$55.05M$3.16B$248.47M7 Day Performance2.21%3.05%2.08%2.92%1 Month Performance-28.09%5.80%4.38%5.77%1 Year Performance-89.32%6.15%35.81%21.39% Mainz Biomed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYNZMainz Biomed2.7455 of 5 stars$1.43+0.1%$14.00+878.3%-89.5%$4.92M$890K-0.0230CARMCarisma Therapeutics2.4368 of 5 stars$0.45+2.2%$1.93+326.9%-70.8%$18.84M$19.63M-0.2920News CoverageGap DownHigh Trading VolumeBIVIBioVie0.727 of 5 stars$1.01-1.9%$3.00+197.0%+139.8%$18.76MN/A-0.1310News CoverageGap DownQTTBQ32 Bio2.7628 of 5 stars$1.53-1.3%$12.17+695.2%-92.0%$18.67M$1.16M-0.3139MTEXMannatech0.6034 of 5 stars$9.42-3.9%N/A+30.1%$17.89M$117.87M-94.16250AYTUAytu BioPharma3.736 of 5 stars$1.98-1.0%N/A-19.9%$17.78M$81M-2.75160News CoverageAnalyst ForecastERNAErnexa Therapeutics0.9637 of 5 stars$2.40-2.0%N/A-92.6%$17.66M$580K-0.2910CINGCingulate3.0163 of 5 stars$4.04-2.4%$26.00+543.6%+1,264.8%$17.17MN/A-0.4820Positive NewsLGVNLongeveron3.6813 of 5 stars$1.15-4.2%$8.67+653.6%-22.6%$17.17M$2.39M-0.1820Gap DownBLRXBioLineRx3.0223 of 5 stars$4.00-5.7%$26.00+550.0%-78.3%$17.04M$28.94M-0.4540News CoverageLEXXLexaria Bioscience3.2488 of 5 stars$0.97+0.7%$7.00+623.8%-67.4%$16.98M$460K-1.647News CoverageAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Carisma Therapeutics Alternatives BioVie Alternatives Q32 Bio Alternatives Mannatech Alternatives Aytu BioPharma Alternatives Ernexa Therapeutics Alternatives Cingulate Alternatives Longeveron Alternatives BioLineRx Alternatives Lexaria Bioscience Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYNZ) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MYNZ Stock Alerts